Current Status and Prospects of Clinical Treatment of Osteosarcoma

Jiang, Zongyuan; Liu, Ji‐Bin; Ma, Yu‐Shui; Fu, Da

doi:10.1177/15330338221124696

Cited by 22 publications

(19 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neoadjuvant chemotherapy, surgery, and postoperative adjuvant chemotherapy are the accepted standard modalities for the treatment of localized osteosarcoma. High-dose methotrexate (HD-MTX), cisplatin (DDP), adriamycin (ADM), ifosfamide (IFO), epirubicin (EPI), and etoposide (VP-16) are commonly used for osteosarcoma chemotherapy [ 12 ]. The MAP regimen composed of HD-MTX, DDP, and ADM is the standard regimen of most treatment centers in Europe and America.…”

Section: Discussionmentioning

confidence: 99%

Research of the Active Components and Potential Mechanisms of Qingfei Gujin Decoction in the Treatment of Osteosarcoma Based on Network Pharmacology and Molecular Docking Technology

Yan

Yang

Yao

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Aim. Qingfei Gujin Decoction (QGD) has been shown to be effective against osteosarcoma. This research was aimed at investigating the main active ingredients and potential mechanisms of QGD acting on osteosarcoma through network pharmacology and molecular docking techniques. Methods. The active ingredients and targets of QGD were screened from the TCMSP database, and the predicted targets were obtained from the PharmMapper database. Meanwhile, the targets of osteosarcoma were collected using OMIM, PharmGKB, and DisGeNET databases. Then, GO and KEGG enrichment analyses were performed by RStudio. PPI and drug-ingredient-target networks were constructed using Cytoscape 3.2.1 to screen the major active ingredients, key networks, and targets. Finally, molecular docking of key genes and their regulatory active ingredients was performed using AutoDockTools 1.5.6 software. Results. 38 active ingredients were collected, generating 89 cross-targets; quercetin, luteolin, β-sitosterol, and kaempferol were the main active ingredients of QGD acting on osteosarcoma, and major signaling pathways such as PI3K-Akt signaling pathway, MAPK signaling pathway, and IL-17 signaling pathway were observed. TP53, SRC, and ESR1 were identified as key proteins that docked well with their regulated compounds. Conclusion. QGD is effective against osteosarcoma through multicomponent, multitarget, and multipathway. This study was helpful for finding effective targets and compounds for osteosarcoma treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Research of the Active Components and Potential Mechanisms of Qingfei Gujin Decoction in the Treatment of Osteosarcoma Based on Network Pharmacology and Molecular Docking Technology

Yan

Yang

Yao

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Non-invasive or minimally invasive ablation techniques, like radiofrequency, thermal, cryoablation, high-intensity focused ultrasound, and microwave ablation, have higher success rates in managing OS than traditional approaches [37,38]. However, as their effectiveness depends on variable factors such as the patient's temperature tolerance and the treatment's ability to penetrate bone tissue, it is challenging to standardize a treatment protocol for OS patients [39].…”

Section: Current Treatment Strategies Against Os and Their Limitationsmentioning

confidence: 99%

Current approaches in tissue engineering-based nanotherapeutics for osteosarcoma treatment

Shanmugavadivu,

Lekhavadhani,

Miranda

et al. 2024

Biomed. Mater.

View full text Add to dashboard Cite

Osteosarcoma (OS) is a malignant bone neoplasm plagued by poor prognosis. Major treatment strategies include chemotherapy, radiotherapy, and surgery. Chemotherapy to treat OS has severe adverse effects due to systemic toxicity to healthy cells. A possible way to overcome the limitation is to utilize nanotechnology. Nanotherapeutics is an emerging approach in treating OS using nanoparticulate drug delivery systems. Surgical resection of OS leaves a critical bone defect requiring medical intervention. Recently, tissue engineered scaffolds have been reported to provide physical support to bone defects and aid multimodal treatment of OS. These scaffolds loaded with nanoparticulate delivery systems could also actively repress tumor growth and aid new bone formation. The rapid developments in nanotherapeutics and bone tissue engineering have paved the way for improved treatment efficacy for OS-related bone defects. This review focuses on current bifunctional nanomaterials-based tissue engineered scaffolds that use novel approaches such as magnetic hyperthermia, photodynamic therapy, photothermal therapy, bioceramic and polymeric nanotherapeutics against OS. With further optimization and screening, nanomaterials-based tissue engineered scaffolds could meet clinical applications for treating OS patients.

show abstract

“…Noteworthy, TKI combined with chemotherapy has been considered during the presurgical neoadjuvant phase to ameliorate the toxic effects of chemotherapy and reduced the duration of therapy. Meanwhile, applicable clinical trials are underway 316,317 …”

Section: Advances In Clinical Research On Targeted Therapy and Immuno...mentioning

confidence: 99%

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

Shen

Lan

et al. 2023

MedComm

View full text Add to dashboard Cite

Osteosarcoma (OS) is a highly prevalent bone malignancy among adolescents, accounting for 40% of all primary malignant bone tumors. Neoadjuvant chemotherapy combined with limb‐preserving surgery has effectively reduced patient disability and mortality, but pulmonary metastases and OS cells' resistance to chemotherapeutic agents are pressing challenges in the clinical management of OS. There has been an urgent need to identify new biomarkers for OS to develop specific targeted therapies. Recently, the continued advancements in genomic analysis have contributed to the identification of clinically significant molecular biomarkers for diagnosing OS, acting as therapeutic targets, and predicting prognosis. Additionally, the contemporary molecular classifications have revealed that the signaling pathways, including Wnt/β‐catenin, PI3K/AKT/mTOR, JAK/STAT3, Hippo, Notch, PD‐1/PD‐L1, MAPK, and NF‐κB, have an integral role in OS onset, progression, metastasis, and treatment response. These molecular classifications and biological markers have created new avenues for more accurate OS diagnosis and relevant treatment. We herein present a review of the recent findings for the modulatory role of signaling pathways as possible biological markers and treatment targets for OS. This review also discusses current OS therapeutic approaches, including signaling pathway‐based therapies developed over the past decade. Additionally, the review covers the signaling targets involved in the curative effects of traditional Chinese medicines in the context of expression regulation of relevant genes and proteins through the signaling pathways to inhibit OS cell growth. These findings are expected to provide directions for integrating genomic, molecular, and clinical profiles to enhance OS diagnosis and treatment.

show abstract

Current Status and Prospects of Clinical Treatment of Osteosarcoma

Cited by 22 publications

References 153 publications

Research of the Active Components and Potential Mechanisms of Qingfei Gujin Decoction in the Treatment of Osteosarcoma Based on Network Pharmacology and Molecular Docking Technology

Research of the Active Components and Potential Mechanisms of Qingfei Gujin Decoction in the Treatment of Osteosarcoma Based on Network Pharmacology and Molecular Docking Technology

Current approaches in tissue engineering-based nanotherapeutics for osteosarcoma treatment

Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies

Contact Info

Product

Resources

About